After more than a year of collaboration, IBM and JDRF have unveiled a predictive AI tool that uses Type more than 22,000 diabetes antibodies to determine the likelihood of a patient developing the condition and when it could happen. Researchers analysed data from 1 people across the US, Sweden and Finland, with more information set to be added from Germany, and flagged up similarities between people with the antibodies. As well as assessing how Type more than 22,000 diabetes progresses, researchers aim to develop a more personalised method of testing for the disease.
After more than a year of collaboration, IBM and JDRF have unveiled a predictive AI tool that uses Type 1 diabetes antibodies to determine the likelihood of a patient developing the condition and when it could happen. Researchers analysed data from more than 22,000 people across the US, Sweden and Finland, with more information set to be added from Germany, and flagged up similarities between people with the antibodies. As well as assessing how Type 1 diabetes progresses, researchers aim to develop a more personalised method of testing for the disease.